

## **DRUG PRIOR AUTHORIZATION COMMITTEE**

### ***March 17, 2005*** **TENTATIVE AGENDA**

|               |   |                                    |
|---------------|---|------------------------------------|
| 10:00 - 10:05 | Welcome, Announcements and Introductions                  | Henry Petry<br>Chairman            |
| 10:05 - 10:15 | Minutes Review  | Discussion/<br>Approval            |
| 10:15- 11:30  | Pharmacy Program/ Budget Update<br>PDL Process Discussion | George Oestreich/<br>Andrew Haslag |
| 11:30 - 11:35 | DUR Update  | Tisha Pomeroy                      |

#### **Old Business**

|               |   |                  |
|---------------|---|------------------|
| 11:35 - 12:05 | Implementation Schedule (Criteria for Previously<br>Approved Clinical Edits, Step Therapies and PA's) | George Oestreich |
|---------------|---|------------------|

#### **New Business**

|               |   |                                    |
|---------------|---|------------------------------------|
| 12:05 – 12:20 | New Drug/Product Reviews<br><b>a.     Proposed Actions</b><br>(See website and Attached Summary)<br>i.     Open Access<br>ii.    Clinical Edit/Step Therapy<br>iii.   Prior Authorization | George Oestreich/<br>Rhonda Driver |
|---------------|---|------------------------------------|

|            |   |                                    |
|------------|---|------------------------------------|
| 12:20-1:45 | <i>Proposed New Program Actions of Existing Products</i><br><b>a.     <u>Clinical Edits</u></b><br>i. <b>Tazorac</b> <ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul><br>ii. <b>Zelnorm</b> <ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li><li>•</li></ul><br>i. <b>Provigil</b> <ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul><br><b>c.     <u>Preferred Drug List (PDL) –Annual Review</u></b><br>i. <b>Cox II Inhibitors</b> <ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul><br>ii <b>Proton Pump Inhibitors</b> <ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul><br>iii. <b>Inhaled Corticosteroids</b> <ul style="list-style-type: none"><li>• Discussion</li><li>• Public Hearing</li><li>• Decision</li></ul> | George Oestreich/<br>Rhonda Driver |
|------------|---|------------------------------------|

- iv. **Beta-Adrenergic Agents/Short Acting**
    - Discussion
    - Hearing
    - Decision
  - v. **Beta-Adrenergic Agents/Nebulized**
    - Discussion
    - Public Hearing
    - Decision
  - vi. **Beta-Adrenergic Agents/Long Acting**
    - Discussion
    - Public Hearing
    - Decision
  - vii. **Beta Blockers**
    - Discussion
    - Public Hearing
    - Decision
  - viii. **Calcium Channel Blockers/Dihydropyridine**
    - Discussion
    - Public Hearing
    - Decision
  - ix. **Calcium Channel Blockers/ Non-Dihydropyridine**
    - Discussion
    - Public Hearing
    - Decision
  - x. **Statins**
    - Discussion
    - Public Hearing
    - Decision
- d.
- i. **Preferred Drug List** / Process discussion
  - ii. **Therapeutic classes/Phase VI**  
To be announced at the meeting.

1:45

## LUNCH

|           |  |                        |
|-----------|--|------------------------|
| 2:00-2:20 | Physician Inquiry  | Allison Lauf/Mary Heet |
| 2:10-2:20 | Other Business <ul style="list-style-type: none"> <li>▪ <i>"Top 25" Drugs by Cost</i></li> <li>▪ <i>Clinical Edit Summary Report</i></li> <li>▪ <i>Call Center Statistics</i></li> </ul> | Rhonda Driver          |

*Informal comments will be accepted from members of the audience at various points in the agenda.  
Times noted are approximate, Agenda may move more quickly*

## Executive Session

|           |                |                        |
|-----------|----------------|------------------------|
| 2:20-2:25 | Minutes Review | Discussion/Approval    |
| 2:25-3:00 | Case Reviews   | Allison Lauf/Mary Heet |

**NEXT MEETING: June 16, 2005**